Therefore, the synthetic lethal relationship based on PARP1 inhibition could be applied to CDK12 mutants, similar to its application to BRCA1 mutants9,45, and CDK12 inhibition might provide a rationale for the use of combination therapy with a PARP inhibitor in CDK12 mutation-related cancers. Here, CDK12 is linked to cancer.